From stealth to breakthrough
From stealth to the eve of commercialization — seven years of brand, strategy, and communications that never broke stride.
A company with world-class science and no public voice
When Praxis came to us, they had everything a precision medicine company needs to succeed — except the brand infrastructure to support it. No market presence. No established narrative. No visual identity capable of carrying a company from its first investor conversation through a decade of clinical development and into commercial launch.
In biopharmaceutical, that gap rarely gets closed well. Companies get built for the raise, or for the trial readout, or for the IPO. The brand drifts between moments. The voice changes with the audience. By the time commercialization arrives, the story is fractured.
We were brought in to make sure that never happened.
Praxis launched in stealth with no external brand presence. We built the identity, the narrative, and the communications architecture from the ground up — before the public even knew the company existed.
CNS precision medicine is technically complex and emotionally charged. The science had to be communicated with rigor to clinicians and investors, and with humanity to patients and families. Most brands choose one register. We built a system that could hold both.
Biopharmaceutical is a space where most companies look, sound, and communicate the same way. Breaking through required a strategic conviction that most agencies won’t commit to — and most clients won’t sustain.
Built to last the distance — not just the announcement
The Praxis visual identity was designed to grow with the company. That was a deliberate choice. Most biotech identities are built for a single stage — the funding round, the conference debut, the IPO roadshow — and then retrofitted as the company evolves. The seams show.
We built a system with enough structural integrity to carry Praxis through every stage of its development without requiring a rebrand at every inflection point. The same identity that introduced Praxis to its first investors presented the company to clinicians, KOLs, and patients. Coherent. Confident. Never outdated.
Scientific precision on one axis. Human purpose on the other. The brand lives at the intersection.
Every stage. Every channel. One unbroken brand.
Seven years in biopharmaceutical means navigating a company through every kind of moment — the ones you plan for and the ones you don’t. Clinical trial results. Regulatory milestones. Pipeline expansions. Market shifts. Leadership transitions. Investor scrutiny. Public narrative.
We have been present for all of it. Not as a vendor brought in for a deliverable, but as the strategic communications partner who understood the company’s vision as well as anyone inside it. That continuity compounded. Every piece of work reinforced what came before it and prepared the ground for what came next.
We built the narrative infrastructure that took Praxis from a company no one had heard of to a credible, differentiated public biotech. Investor materials, IPO positioning, corporate story — all grounded in a brand framework designed to hold up under scrutiny.
Clinical trials don’t pause for brand consistency. We maintained clear, strategic communications through every phase — pipeline updates, trial data communications, KOL engagement, conference presence — without ever losing the thread of who Praxis is and what they stand for.
With dual launches in essential tremor and epilepsy approaching, we built the commercial communications architecture to match. Disease awareness. Physician engagement. Patient community. Each channel calibrated. All of it connected.
The brand that Has held through every stage of development
Part Human has been Praxis’s brand and communications partner from the beginning. That means everything we’ve built connects. The investor materials speak the same language as the patient communications. The conference presence reflects the same vision as the corporate website. The clinical-stage brand is the same brand that will carry the commercial launch.
That kind of coherence doesn’t happen by accident. It happens when strategy and execution stay in the same hands across the full arc of a company’s growth.
